Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers target inflammatory mediators produced during arachidonic acid metabolism. They operate through two mechanisms: 5-lipoxygenase inhibitors like zileuton prevent leukotriene synthesis, while leukotriene receptor antagonists like zafirlukast and montelukast block LTD4 binding to respiratory mucosa receptors. This reduces bronchoconstriction and inflammation, improving airflow and alleviating asthma symptoms.

Zileuton inhibits 5-lipoxygenase, an enzyme crucial for synthesizing leukotrienes, preventing inflammatory substance formation. Zafirlukast and montelukast, conversely, block leukotriene-D4 from binding to its receptor on respiratory tract cells. Both approaches mitigate bronchoconstriction and inflammation, but zileuton stops leukotriene production while receptor antagonists prevent their effects after synthesis.

Oral administration enhances patient compliance, particularly in children who struggle with inhalation therapies like inhalers or nebulizers. This ease of use makes leukotriene modifiers more practical for chronic asthma management. Oral delivery ensures consistent medication adherence, which is essential for maintaining effective long-term asthma control in pediatric and adult populations.

Common adverse effects in adults include headache, nausea, abdominal pain, and cough. Rarely, psychological effects such as mood changes and nightmares may occur and require prompt medical attention. While leukotriene modifiers are generally safe and well-tolerated, any concerning symptoms should be reported to a healthcare professional for evaluation and management.

Leukotriene modifiers target specific inflammatory mediators in arachidonic acid metabolism, offering an alternative mechanism to inhaled corticosteroids. While both reduce inflammation and improve airflow, they work through different pathways. Leukotriene modifiers' oral administration may provide better compliance in children, complementing antiasthma drugs inhaled corticosteroids and glucocorticoids in comprehensive asthma treatment strategies.

Children may experience nausea, diarrhea, sinusitis, and viral infections when taking leukotriene modifiers. Parents and caregivers should monitor for these symptoms and consult a healthcare provider if they arise. Despite these potential side effects, leukotriene modifiers remain valuable for managing chronic asthma in pediatric populations.

5-lipoxygenase is a crucial enzyme in synthesizing leukotrienes, inflammatory substances that cause bronchoconstriction and increase lung mucus production. By inhibiting this enzyme, drugs like zileuton prevent leukotriene formation, reducing inflammation and airway constriction. This mechanism directly addresses the inflammatory cascade underlying asthma pathogenesis and symptom development.